Log in to search using one of your social media accounts:

 

Funding for gene therapy to injured peripheral nerves

(University of Plymouth) Scientists from Plymouth University Peninsula Schools of Medicine and Dentistry have received funding from the Northcott Devon Medical Foundation to explore the potential of gene therapy as a way to enhance functional recovery following microsurgery for injured peripheral nerves.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news

Related Links:

The first human trial of gene therapy to treat respiratory problems in early-onset Pompe disease of children was found safe, according to health researchers.
Source: Health News - UPI.com - Category: Consumer Health News Source Type: news
Contributors : Pratiksha I Thakore ; Jennifer B Kwon ; Christopher E Nelson ; Douglas C Rouse ; Matthew P Gemberling ; Matthew L Oliver ; Charles A GersbachSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusCRISPR-Cas9 transcriptional repressors have emerged as robust tools for disrupting gene regulation in vitro but have not yet been adapted for delivery in adult animal models. Here we created an S. aureus Cas9-based transcriptional repressor (dSaCas9KRAB) compatible with adeno-associated viral (AAV) delivery. To evaluate dSaCas9KRAB efficacy for targeting an endogenous gene in vivo, we...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Mus musculus Source Type: research
In this study, we used concomitant intratumoral GET of two cytokines: tumor necrosis factor alpha (TNF α), a potent cytotoxic cytokine to induce in situ vaccination, and interleukin 12 (IL-12), an immunostimulatory cytokine to boost the primed local immune response into a systemic one. After performing GET in murine melanoma tumors, both TNFα and IL-12 mRNA levels were significantly increased, whic h resulted in a pronounced delay in tumor growth of 27 days and a prolonged survival time of mice. An antitumor immune response was confirmed by extensive infiltration of immune cells in the tumor site, and expansion...
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
Voyager will make gene therapies to deliver AbbVie antibodies that target tau, a protein associated with Alzheimer ’s
Source: Chemical and Engineering News - Category: Chemistry Authors: Source Type: research
(MedPage Today) -- Also, gene therapy approved for retinal dystrophy
Source: MedPage Today Primary Care - Category: Primary Care Source Type: news
In 2011 a research group published the results from an animal study that demonstrated, in a way that couldn't be ignored, that the accumulation of senescent cells is a significant cause of aging and age-related disease. In fact, the evidence for this to be the case had been compelling for a very long time - this demonstration came nearly a decade after Aubrey de Grey, on the basis of the existing evidence at the time, included cellular senescence as one of the causes of aging in the first published version of his SENS research proposals. Yet nothing had been done to move ahead and achieve something with this knowledge. Tha...
Source: Fight Aging! - Category: Research Authors: Tags: Medicine, Biotech, Research Source Type: blogs
Voyager Therapeutics said Tuesday that it will work with AbbVie to develop gene therapy treatments for Alzheimer ’s disease in a deal worth at least $69 million for the Cambridge biotech. The announcement by Voyager (Nasdaq: VYGR) and Chicago-based AbbVie (NYSE: ABBV) comes as drug developers are exploring new approaches to Alzheimer’s following a string of recent clinical setbacks. Gene therapies — dru gs that work by inserting healthy genes into a person’s cells to replace faulty or missing…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news
Electric stimulation of the auditory nerve by cochlear implants has been a successful clinical intervention to treat the sensory neural deafness. In this pathological condition of the cochlea, type-1 spiral ganglion neurons in Rosenthal's canal play a vital role in the action potential initiation. Various morphological studies of the human temporal bones suggest that the spiral ganglion neurons are surrounded by heterogeneous structures formed by a variety of cells and tissues. However, the existing simulation models have not considered the tissue heterogeneity in the Rosenthal's canal while studying the elec...
Source: IEEE Transactions on Biomedical Engineering - Category: Biomedical Engineering Source Type: research
ConclusionBy extrapolating our murine data, and data from some previous studies to a human non‐conditioned autologous CD34+ HSPC transplantation setting, we conclude that approximately 44 million CD34+ HSPCs would be needed to achieve 20% donor chimerism in a 70‐kg human, which could serve as a starting point for the future use of HSCPs in gene and cell therapy.
Source: European Journal of Haematology - Category: Hematology Authors: Tags: ORIGINAL ARTICLE Source Type: research
Gene therapies involve delivering instructions into cells to ensure that specific proteins are manufactured, either temporarily or permanently. This is effectively a hijacking or programming of cellular mechanisms. There is another approach, which is to deliver suitable DNA machinery into the body, capable of manufacturing the desired proteins outside cells. This isn't helpful for all types of protein, but in many cases it is. That machinery needs protection, however: naked, it would be quickly removed by the immune system or otherwise broken down. One possibility is to employ engineered bacteria, which removes the need to...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs
More News: Dentistry | Funding | Gene Therapy | Genetics | International Medicine & Public Health | Schools